NCT07076550
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07076550
Title A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Alpha-9 Oncology USA Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.